| Literature DB >> 29977832 |
Yasamin Baghdadchi1, Maryam Khoshkam2, Mojtaba Fathi1,3, Ahmad Jalilvand1, Koorosh Fooladsaz1, Ali Ramazani3.
Abstract
Introduction: There is a fundamental need to characterize multiwalled carbon nanotubes (MWCNTs) toxicity to guarantee their safe application. Functionalized MWCNTs have recently attracted special interest in order to enhance biocompatibility. The aim of the current work was to study the underlying toxicity mechanism of the -OH-functionalized MWCNTs (MWCNTs-OH), using the powerful NMR-based metabonomics technique.Entities:
Keywords: Chemometrics; Metabolomics; Multi-walled carbon nanotubes; NMR; Toxicity
Year: 2017 PMID: 29977832 PMCID: PMC6026527 DOI: 10.15171/bi.2018.13
Source DB: PubMed Journal: Bioimpacts ISSN: 2228-5652
Fig. 1
Fig. 2Comparison of biochemical parameters between groups and time points
|
|
|
|
|
|
|
|
|
|
|
|
|
| C24 | 112±2.0 | 0.5±0.05 | 180±4.0 | 29.2±0.2 | 75±3.0 | 154±5.0 | 469±17.0 | 154±4.0 | 1446±406 | 0.14±0.03 | 3.3±0.1 |
| L24 | 104±2.0 | 0.46±0.04 | 132±2.0 | 26.5±.0.5 | 71±6.0 | 211±7.0 | 365±5.0 | 163±6.0 | 2771±510 | 0.16±0.01 | 3.1±0.3 |
| M24 | 103±4.0 | 0.4±0.02 | 251±5.0 | 25.6±0.2 | 48±11.0 | 196±6.0 | 240±4.0 | 141±1000 | 3228±425 | 0.13±0.02 | 3.1. ±0.1 |
| H24 | 109±3.0b | 0.44±0.05 | 177±4.0b,c | 25 ±0.5a,b | 42±9.0a | 113±9.0b | 428±13.0 | 176±6.0a | 1844±514 | 0.1±0.01b | 2.9±0.05a |
| C48 | 138±7.0 | 0.48±0.05 | 122±7.0 | 34.5±0.5 | 120±20 | 184±3.0 | 291±17.0 | 174±5.0 | 1915±471 | 0.2±0.04 | 3.4±.04 |
| L48 | 76±6.0 | 0.5±0.3 | 125±2.0 | 35.8±5.0 | 56±9.0 | 198±7.0 | 126±6.0 | 94±11.0 | 2752±462 | 0.10±0.03 | 3.4±0.3 |
| M48 | 123±3.0 | 0.5±0.05 | 153±7.0 | 38.7±5.0 | 46±2.0 | 109±4.0 | 447±7.0 | 192±10.0 | 1627±505 | 0.10±0.02 | 3.4±0.7 |
| H48 | 113±3.0b | 0.58±0.03 | 218±2.0a,b | 32.1±0.2a | 64±5.0 | 129±5.0 | 424±5.0 | 192±19.0 | 1124±480 | 0.12±0.03 | 3.0±0.5 |
| C7 | 92±4.0 | 0.46±0.05 | 140±4.0 | 24±2.0 | 40±19.0 | 212±11.0 | 204±11.0 | 168±8.0 | 4306±456 | 0.06±0.05 | 2.6±0.1 |
| L7 | 72±2.0 | 0.4±0.03 | 88±3.0 | 32.4±0.1 | 62±4.0 | 354±4.0 | 304±8.0 | 134±5.0 | 4874±522 | 0.08±0.02 | 2.6±0.4 |
| M7 | 108±5.0 | 0.44±0.04 | 96±5.0 | 27.8±3.0 | 42±8.0 | 268±6.0 | 304±2.0 | 192±6.0 | 4584±424 | 0.07±0.03 | 3±0.2 |
| H7 | 88±2.0 | 0.48±0.05 | 106±10.0a | 26±4.0 | 44±3.0 | 330±8.0 | 278±15.0a | 178±5.0,0 | 4560±490 | 0.1±0.03 | 3±0.5 |
| C24 | 77±4.0 | 0.5±0.3 | 142±2.0 | 26.4±0.1 | 51±6.0 | 188±5.0 | 201±8.0 | 106±5.0 | 4290±466 | 0.13±0.04 | 2.7±0.3 |
| L24 | 119±6.0 | 0.45±0.12 | 224±3.0 | 26±6.0 | 54±5.0 | 220±9.0 | 231±15.0 | 166±3.0 | 3267±524 | 0.12±0.02 | 2.8±0.9 |
| M24 | 115±10.0 | 0.6±0.2 | 157±8.0 | 27.9±2.65 | 54±4.0 | 163±2.0 | 299±6.0 | 193±3.0 | 3163±490 | 0.13±0.03 | 3.1±0.3 |
| H24 | 88±8.0 | 0.5±0.1 | 134±4.0b | 27.3±0.3 | 64±7.0 | 218±12.0 | 259±3.0 | 190±10.0 | 3200±511 | 0.16±0.02 | 3.3±0.4 |
Tc: Total cholesterol (mg/dL). LDL: Low density lipoprotein (mg/dL). Cr: Creatinine (mg/dL). TG: Triglyceride (mg/dL). BUN: Blood urea nitrogen (mg/dL). ALT: Alanine aminotransferase (IU/L). AST: Aspartate aminotransferase(IU/L). ALP: Alkaline phosphatase (IU/L). Glc: Glucose (mg/dL). LDH: Lactate dehydrogenase (IU/L). BIL: Bilirubin (mg/dL). ALB: Albumin (g/dL). C24: Control group at 24 h. L24: L-dose group at 24 h. M24: M-dose group at 24 h. H24: H-dose group at 24 h. C48: Control group at 48 h. L48: L-dose group at 48 h. M48: M-dose group at 48 h. H48: H-dose group at 48 h. Moreover, the groups in each time-point were shown with the same color. Altered parameters were indicated by a(Compared to the control group, P < 0.05), b(Compared to the Low-dose group, P < 0.05) and c(Compared to the Medium-dose group, P < 0.05).
Fig. 3The MWCNTs-OH induced variation in the endogenous metabolites compared to control group
|
|
|
|
|
|
|
|
| 1 | Cholesterol | HMDB00067 | 0.66(s), 1.17(m), 6.38(s), 6.62(s) | ↓ | ↑ | ↑ |
| 2 | Cholesterol sulfate | HMDB00653 | 0.82(s), 1.35(m), 1.45(m), 6.41(s), 6.62(s) | ↑ | ↑ | ↑ |
| 3 | Estradiol | HMDB00151 | 0.67(s), 3.71(s) | ↓ | ↑ | ↑ |
| 4 | Estriol | HMDB00153 | 0.83(s), 3.71(s) | ↓ | ↑ | ↑ |
| 5 | Estrone | HMDB00145 | 0.96(s), 0.95(m), 0.88(d), 0.63(s) | ↓ | ↑ | ↑ |
| 6 | 2-Methoxyestradiol | HMDB00405 | 1.17(s), 1.21(s), 3.31(s), 5.62(s) | ↑ | ↑ | ↑ |
| 7 | 2-Hydroxyestradiol | HMDB03962 | 1.761(m), 1.765(m), 1.777(m), 1.782(m), 2.234(t), 2.326(m), 2.335(m) | ↑ | ↑ | ↑ |
| 8 | 16α-Hydroxyestrone | HMDB00335 | 0.9(s), 1.05(s), 1.57(m) | ↑ | ↑ | ↑ |
| 9 | 2-Hydroxyestrone | HMDB00343 | 0.92(s), 1.21 (s) | ↑ | ↑ | ↑ |
| 10 | 2-Methoxyestrone | HMDB00010 | 0.68(s), 0.81-0.85(m), 0.92-0.93(m) | ↑ | ↑ | ↑ |
| 11 | Ethiocolanolone | HMDB00490 | 0.68(s), 0.79(m), 0.85(dd), 0.96(m), 1.01(m), 1.55(s) | ↑ | ↑ | ↑ |
| 12 | Testosterone | HMDB00234 | 1.54(m), 1.01(s), 0.85(d)-0.92(d), 0.68(s) | ↑ | ↑ | ↑ |
| 13 | Androstendione | HMDB00053 | 1.54(m), 1.01(s), 0.85(d)-0.92(d), 0.68(s) | ↓ | ↓ | ↑ |
| 14 | Androstanedione | HMDB00899 | 0.65(s), 0.84-0.85(dd), 0.89-0.90(m), 0.95 | ↑ | ↑ | ↑ |
| 15 | Dehydroepiandrosterone | HMDB00077 | 0.81(s), 1.38(s) | ↑ | ↑ | ↑ |
| 16 | 17α-Hydroxypregnenolone | HMDB00363 | 0.47(s), 1.32(m), 2.13(m), 5.64(s) | ↓ | ↑ | ↑ |
| 17 | 17-Hydroxyprogesterone | HMDB00374 | 1.66(m), 1.03(s), 0.88(s) | ↓ | ↑ | ↑ |
| 18 | 17α,20α-Dihydroxypregn-4-en-3-on | HMDB11653 | 0.7(s), 1.19(s) | ↑ | ↓ | ↑ |
| 19 | Cortisone | HMDB02802 | 0.66(s), 3.51(s), 6.42-6.43(d), 7.03-7.04(m) | ↑ | ↓ | ↑ |
| 20 | Corticosterone | HMDB01547 | 0.66(s), 1.23(m), 2.68(m), 3.29(t), 6.42(d), 650(dd), 7.03(d) | ↓ | ↑ | ↑ |
| 21 | Progesterone | HMDB01830 | 0.86(s), 0.98(s) | ↑ | ↑ | ↑ |
| 22 | Deoxycorticoesterone | HMDB00016 | 0.535(s), 0.797(s), 0.87(dd), 0.92(d), 1.37(s) | ↑ | ↑ | ↑ |
| 23 | Aldosterone | HMDB00037 | 5.74(s), 2.13(s), 1.2(s), 0.68(s) | ↑ | ↑ | ↑ |
| 24 | L-Lysine | HMDB00182 | 1.74-1.77(m), 1.9(m), 2.06-2.07(q), 2.37-2.40(t), 3.03-3.06(td), 3.58-3.60(t), 3.73-3.76(t) | ↑ | ↑ | ↑ |
| 25 | Saccharopine | HMDB00279 | 0.804(s), 1.206(s), 1.564(m) | ↑ | ↓ | ↓ |
| 26 | Aminoadipate | HMDB00510 | 0.66(s), 1.17(m), 6.38(s),6.62(s) | ↑ | ↓ | ↑ |
| 27 | Biotin | HMDB00030 | 0.82(s), 1.35(m), 1.45(m), 6.41(s), 6.62(s) | ↑ | ↓ | ↓ |
| 28 | Biocytin | HMDB03134 | 0.67(s), 3.71(s) | ↓ | ↓ | ↓ |
| 29 | Taurine | HMDB00251 | 0.83(s), 3.71(s) | ↑ | ↑ | ↑ |
| 30 | Taurocholic acid | HMDB00036 | 0.96(s), 0.95(m), 0.88(d),0.63(s) | ↓ | ↑ | ↑ |
| 31 | Pipecolic acid | HMDB00070 | 1.17(s), 1.21(s), 3.31(s), 5.62(s) | ↑ | ↓ | ↓ |
The altered metabolic pathways in serum samples due to MWCNTs-OH administration
|
|
|
|
|
|
|
| Steroid hormone biosynthesis | 72 | 23 | 5.1944E-7 | 4.2594E-5 | 0.58352 |
| Lysine biosynthesis | 4 | 3 | 0.0046416 | 0.19031 | 0.0 |
| Biotin metabolism | 5 | 3 | 0.01068 | 0.29191 | 0.7 |
| Taurine and hypotaurine metabolism | 8 | 2 | 0.21281 | 1.0 | 0.42857 |
| Lysine degradation | 23 | 4 | 0.23462 | 1.0 | 0.01471 |
Hits is the actually matched number from the user uploaded data, Raw p is the original p value calculated from the enrichment analysis, FDR p is the p value adjusted using False Discovery Rate, Impact is the pathway impact value calculated by pathway topology analysis.
Fig. 4